cabergoline has been researched along with Multiple Endocrine Neoplasia Type 1 in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Groß, U; Iacovazzo, D; Jungheim, K; Koehler, VF; Korbonits, M; Mann, A | 1 |
Nakakuki, T; Nanba, K; Shimatsu, A; Usui, T | 1 |
Camera, L; Carratù, A; Colao, A; de Luca di Roseto, C; Del Prete, M; Di Somma, C; Faggiano, A; Marciello, F; Marotta, V; Ramundo, V | 1 |
3 other study(ies) available for cabergoline and Multiple Endocrine Neoplasia Type 1
Article | Year |
---|---|
Novel Germline p.Gly42Val
Topics: Adult; Amino Acid Substitution; Antineoplastic Agents; Cabergoline; Combined Modality Therapy; Dopamine Agonists; Ergolines; Family Health; Germ-Line Mutation; Heterozygote; Humans; Male; Multiple Endocrine Neoplasia Type 1; Mutation, Missense; Pancreatectomy; Parathyroidectomy; Proto-Oncogene Proteins; Treatment Outcome | 2017 |
Tension pneumocephalus after administration of two 0.25 mg cabergoline tablets in MEN1-related macroprolactinoma.
Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Humans; Magnetic Resonance Imaging; Male; Multiple Endocrine Neoplasia Type 1; Pneumocephalus; Prolactinoma; Tablets | 2013 |
Combined biological therapy with lanreotide autogel and cabergoline in the treatment of MEN-1-related insulinomas.
Topics: Adult; Antineoplastic Agents; Cabergoline; Drug Therapy, Combination; Ergolines; Humans; Insulinoma; Male; Multiple Endocrine Neoplasia Type 1; Pancreatic Neoplasms; Peptides, Cyclic; Somatostatin; Treatment Outcome | 2014 |